Evidence map›Paper›PMID 40255727›Full record

ArticleCureus2025

Exploring Acute Pancreatitis After Orlistat Use: A Case Report.

Abeer Qasim, Abhilasha Jyala, Ornela Thartori, Haider Ghazanfar, Sarah Moore, Elona Shehi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abeer QasimInternal Medicine, BronxCare Health System, Bronx, USA.
Abhilasha JyalaInternal Medicine, BronxCare Health System, Bronx, USA.
Ornela ThartoriInternal Medicine, BronxCare Health System, Bronx, USA.
Haider GhazanfarInternal Medicine, BronxCare Health System, Bronx, USA.
Sarah MooreObstetrics and Gynecology, American University of the Caribbean School of Medicine, Cupecoy, SXM.
Elona ShehiGastroenterology, BronxCare Health System, Bronx, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orlistat is an FDA-approved medication for obesity management that functions as a pancreatic lipase inhibitor. This medication is accessible without a prescription in numerous developed nations. As its utilization rises, the likelihood of experiencing adverse events also increases. A thorough understanding of these events is crucial for making informed decisions and ensuring effective management. We describe the case of a 23-year-old female who presented with acute pancreatitis after she started orlistat. We reviewed the association between orlistat use and acute pancreatitis, analyzing clinical cases and potential risk factors. By examining available medical literature and case studies, our study aims to provide insights into the correlation between orlistat therapy and the manifestation of acute pancreatitis.

Indexed as

calciumdrug-inducedetiologyorlistatpancreatitisrisk factors: orlistat

Identifiers

PMID40255727
PMCPMC12007682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.